Clinical Validation of Early Detection Blood Test for Universal Large-scale Breast Cancer Screening
NCT07219277
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
Breast cancer is the most common cancer that spreads beyond the initial layer of tissue it developed in, and grows into surrounding healthy tissue in women worldwide. It is associated with significant illness and death. Identifying the disease in the early stage is important to achieving positive outcomes in response to diagnosis and treatment. The Syantra blood test has been developed over the past 10 years. This test involves examining blood samples to identify and analyze specific information.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Breast Cancer, Liquid Biopsy, Early Detection
Eligibility basics and study details
- Study type
- Observational
- Phase
- Not applicable
- Ages
- 30 to 75 years
- Sex
- Female
- Healthy volunteers
- Accepted
- Sponsor
- Syantra Inc.
- Last updated on ClinicalTrials.gov
- March 11, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Arizona · 1
- Vincere Cancer Center · Phoenix, AZ
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.